← All trials
NCT03757000
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2017
- Primary completion
- Mar 30, 2019
- Completion date
- May 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai YingLi Pharmaceutical Co. Ltd.Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.